Nvelop Therapeutics, founded in Cambridge, Massachusetts, is a biotechnology company dedicated to developing transformational genetic medicines using novel gene editing delivery technologies. The company's core mission is to address significant unmet medical needs by advancing innovative approaches to deliver therapeutic payloads, particularly focusing on gene editing in relevant cells and tissues. Nvelop Therapeutics aims to revolutionize the treatment landscape for major diseases through its cutting-edge solutions.

Notable affiliated individuals include Professor David Liu from HHMI, Broad Institute, and Harvard, and Professor Keith Joung from MGH and Harvard. These world-class scientific founders bring extensive expertise and credibility to the company. Nvelop Therapeutics has made significant strides in the biotechnology sector, contributing to the advancement of gene editing technologies. Their impactful work holds promise for addressing critical healthcare challenges and improving patient outcomes worldwide.